WEP Clinical (WEP), the specialist pharmaceutical services company, has partnered with Mylan N.V. (Mylan), a global pharmaceutical company, to launch a Named Patient Access Program (NPAP) for a new chemical entity used to treat highly drug-resistant forms of tuberculosis (TB).  The NPAP is designed specifically to address physicians’ requests for those individual patients who live in countries where regulatory approval for the product is not yet available.

TB is the world’s leading cause of death from a single infectious disease globally, resulting in 1.5M deaths a year.[1] Unfortunately, due to growing resistance to TB drugs, highly drug-resistant forms of TB are becoming a major global health problem that threatens the progress made in TB treatment and care around the world.

Through the NPAP, WEP and Mylan will work in conjunction with major global health partners to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving Mylan approval, can request this product as a treatment option for patients, irrespective of where they live.

About WEP Clinical

WEP Clinical is a specialist pharmaceutical services company that partners with drug developers to make much-needed medicines available around the world. It supports its partner companies with all elements involved in product distribution and approval at the local level. WEP Clinical has offices in the US, UK, Ireland and Portugal and has comprehensive regulatory and shipping knowledge, resulting in true global project management and distribution capabilities for customers.


[1] Global tuberculosis report [Internet]. WHO. 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1